{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:15:53Z","timestamp":1783646153066,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Nitroxolin z\u00e4hlt entsprechend der AWMF-S3-Leitlinie zu den Antibiotika der ersten Wahl f\u00fcr die Behandlung der unkomplizierten Zystitis (UZ) bei Frauen. Unter Real-world-Bedingungen sollte die klinische Effektivit\u00e4t von Nitroxolin in einer prospektiven, multizentrischen, nicht-interventionellen Studie (NIS) und die Resistenz von <jats:italic>Escherichia\u00a0coli<\/jats:italic> gegen\u00fcber Nitroxolin \u00fcberpr\u00fcft werden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Patientinnen mit UZ und einer Therapie mit Nitroxolin (empfohlene Dosierung 3\u202f\u00d7\u2009t\u00e4glich 250\u202fmg \u00fcber 5\u00a0Tage) wurden von Urologen, Allgemeinmedizinern und haus\u00e4rztlich t\u00e4tigen Internisten deutschlandweit von April bis Dezember 2022 rekrutiert und \u00fcber einen Zeitraum von 21\u201328\u00a0Tagen nachverfolgt. Die Diagnosestellung und der Therapieverlauf wurden mit Hilfe des ACSS-Fragebogens und anhand von Laboruntersuchungen (Leukozyturie etc.) beurteilt. Unabh\u00e4ngig von der NIS wurden im Rahmen einer bundesweiten Resistenz-Surveillance im Zeitraum 2019\u201320 in 23\u00a0Laboratorien <jats:italic>Escherichia-coli<\/jats:italic>-Urinisolate gesammelt und deren Empfindlichkeit gegen\u00fcber Nitroxolin getestet.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Von 316\u00a0Patientinnen im mittleren (SD) Alter von 57,2 (\u00b120,4; Median 62,5) Jahren, die in die NIS eingeschlossen wurden, war die Therapie zum Zeitpunkt des \u201etest of cure\u201c bei 193\/248 (86,3\u202f%) in der Per-protocol-Gruppe und 193\/263 (81,4\u202f%) in der Intention-to-treat-Gruppe klinisch erfolgreich. 96\u202f% der Patientinnen bewerteten die Vertr\u00e4glichkeit von Nitroxolin als \u201esehr gut\u201c oder \u201egut\u201c. Alle 272 getesteten <jats:italic>Escherichia-coli<\/jats:italic>-Isolate waren Nitroxolin-sensibel.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Nitroxolin erzielte sehr gute klinische Ergebnisse in der NIS und wies eine sehr g\u00fcnstige Resistenzsituation bei <jats:italic>Escherichia-coli<\/jats:italic>-Urinisolaten auf. Nitroxolin kann weiterhin als Antibiotikum der ersten Wahl zur Behandlung der UZ der Frau empfohlen werden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00120-023-02167-5","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T13:01:50Z","timestamp":1693486910000},"page":"1186-1192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapie der Zystitis mit Nitroxolin\u00a0\u2013 NitroxWin","Therapy of cystitis with nitroxoline\u2014NitroxWin"],"prefix":"10.1007","volume":"62","author":[{"given":"Florian","family":"Wagenlehner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kresken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bahrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Grabein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Ludwig","family":"Strohmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt G.","family":"Naber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"2167_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00120-015-3873-5","volume":"54","author":"JF Alidjanov","year":"2015","unstructured":"Alidjanov\u00a0JF, Pilatz\u00a0A, Abdufattaev\u00a0UA, Wiltink\u00a0J, Weidner\u00a0W, Naber\u00a0KG, Wagenlehner\u00a0F (2015) Deutsche Validierung des \u201eAcute Cystitis Symptom Score\u201c. Urologe 54:1269\u20131276","journal-title":"Urologe"},{"key":"2167_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00120-017-0327-2","volume":"56","author":"JF Alidjanov","year":"2017","unstructured":"Alidjanov\u00a0JF, Pilatz\u00a0A, Abdufattaev\u00a0UA, Wiltink\u00a0J, Weidner\u00a0W, Naber\u00a0KG, Wagenlehner\u00a0F (2017) Kommentar zum Beitrag: \u201eAcute Cystitis Symptom Score\u201c. Urologe 2015;54:1269\u201376. Neuer Fragebogen zur deutschen Validierung des \u201eAcute Cystitis Symptom Score\u201c. Urologe 56:364\u2013366","journal-title":"Urologe"},{"key":"2167_CR3","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00345-019-02948-8","volume":"38","author":"JF Alidjanov","year":"2020","unstructured":"Alidjanov\u00a0JF, Naber\u00a0KG, Pilatz\u00a0A, Radzhabov\u00a0A, Zamuddinov\u00a0M, Magyar\u00a0A, Tenke\u00a0P, Wagenlehner\u00a0F (2020) Additional assessment of Acute Cystitis Symptom Score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II. World J Urol 38:1977\u20131988","journal-title":"World J Urol"},{"key":"2167_CR4","unstructured":"European Medicines Agency Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, Revision 3. In: European Medicines Agency; EMA\/844951\/2018 Rev. 3. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf. Zugegriffen: 5. Febr. 2023"},{"key":"2167_CR5","unstructured":"Food and Drug Administration Uncomplicated urinary tract infections: developing drugs for treatment. Guidance for industry (2019). In: U.S. Department of health and human services, food and drug administration, center for drug evaluation and research (CDER). https:\/\/www.fda.gov\/media\/129531\/download. Zugegriffen: 5. Febr. 2023"},{"key":"2167_CR6","doi-asserted-by":"publisher","first-page":"5S","DOI":"10.1016\/S0002-9343(02)01054-9","volume":"113","author":"B Foxman","year":"2002","unstructured":"Foxman\u00a0B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113:5S\u201313S","journal-title":"Am J Med"},{"key":"2167_CR7","unstructured":"(2022) EAU Guidelines Urological Infections. https:\/\/ uroweb.ord\/guidelines\/urological-infections\/summary-of-changes. Zugegriffen: 5. Febr. 2023"},{"issue":"8","key":"2167_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5414\/NHX1862","volume":"46","author":"J Kranz","year":"2017","unstructured":"Kranz\u00a0J, Schmidt\u00a0S, Leber\u00a0C, F\u00fcnfst\u00fcck\u00a0R, Helbig\u00a0S, Hofmann\u00a0W, Hummers\u00a0E, Kunze\u00a0M, Kniehl\u00a0E, Naber\u00a0K, Mandraka\u00a0F, M\u00fcndner-Hensen\u00a0B, Schneidewind\u00a0L, Sester\u00a0U, Vahlensieck\u00a0W, Schmiemann\u00a0G, Wagenlehner\u00a0F (2017) Interdisziplin\u00e4re AWMF S3-Leitlinie: Epidemiologie, Diagnostik, Therapie, Pr\u00e4vention und Management unkomplizierter bakterieller ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten.(Kurzfassung). Nieren Hochdruckkrankheiten 46(8):334\u2013385","journal-title":"Nieren Hochdruckkrankheiten"},{"key":"2167_CR9","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.1128\/AAC.03946-14","volume":"58","author":"M Kresken","year":"2014","unstructured":"Kresken\u00a0M, K\u00f6rber-Irrgang\u00a0B (2014) In vitro activity of nitroxoline against escherichia coli urine isolates from outpatient departments in Germany. Antimicrob Agents Chemother 58:7019\u20137020","journal-title":"Antimicrob Agents Chemother"},{"key":"2167_CR10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/antibiotics11060751","volume":"1","author":"M Kresken","year":"2022","unstructured":"Kresken\u00a0M, Pfeifer\u00a0Y, Wagenlehner\u00a0F, Werner\u00a0G, Wohlfarth\u00a0E (2022) Resistance to mecillinam and nine other antibiotics for oral use in escherichia coli isolated from urine specimens of primary care patients in Germany, 2019\/20. Antibiotics 1:751. https:\/\/doi.org\/10.3390\/antibiotics11060751","journal-title":"Antibiotics"},{"key":"2167_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12879-014-0628-7","volume":"14","author":"KG Naber","year":"2014","unstructured":"Naber\u00a0KG, Niggemann\u00a0H, Stein\u00a0G, Stein\u00a0G (2014) Review of the literature and individual patients\u2019 data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections. BMC Infect Dis 14:628\u2013643","journal-title":"BMC Infect Dis"},{"issue":"3","key":"2167_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/jacamr\/dlac059","volume":"4","author":"L Plambeck","year":"2022","unstructured":"Plambeck\u00a0L, Fuchs\u00a0F, Sattler\u00a0J, Hamprecht\u00a0A (2022) In vitro activity of mecillinam, temocillin and nitroxoline against MDR enterobacterales. JAC Antimicrob Resist 4(3):16","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"2167_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijantimicag.2017.10.010","volume":"51","author":"A Sobke","year":"2018","unstructured":"Sobke\u00a0A, Makarewicz\u00a0O, Baier\u00a0M, B\u00e4r\u00a0C, Pfister\u00a0W, Gatermann\u00a0SG, Pletz\u00a0MW, Forstner\u00a0C (2018) Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline. Int J Antimicrob Agents 51(2):213\u2013220","journal-title":"Int J Antimicrob Agents"},{"key":"2167_CR14","unstructured":"Wagenlehner F, Schmiemann G, F\u00fcnfst\u00fcck R, Helbig S, Hofmann W, Hoyme U, Hummers-Pradier E, Kunze M, Kaase M, Kranz J, Kniehl E, Lebert C, Mandraka F, M\u00fcndner-Hensen B, Naber KG, Schneidewind L, Schmidt S, Selbach I, Sester U, Vahlensieck W, Watermann D (2017) Epidemiologie, Diagnostik, Therapie, Pr\u00e4vention und Management unkomplizierter bakterieller ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. S3-Leitlinie, AWMF Registernummer: 043\/044. Aktualisierung 04\/2017. Langversion. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/043-044l_S3_Harnwegsinfektionen_2017-05.pdf. Zugegriffen: 5. Febr. 2023"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02167-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-023-02167-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02167-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T15:02:32Z","timestamp":1699369352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-023-02167-5"}},"subtitle":["Prospektive, multizentrische, nicht-interventionelle Studie und mikrobiologische Untersuchungen zur Resistenzsituation","Prospective, multicenter, non-interventional study and microbiological resistance surveillance"],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2167"],"URL":"https:\/\/doi.org\/10.1007\/s00120-023-02167-5","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"assertion":[{"value":"19 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Wagenlehner, M.\u00a0Kresken, C.\u00a0Bahrs, B.\u00a0Grabein, W.L.\u00a0Strohmaier, K.G.\u00a0Naber sind Mitglieder des wissenschaftlichen Beirats der MIP Pharma. E.\u00a0Wohlfarth gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen wurden im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}